Cargando…
Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis
BACKGROUND: The refractory/relapsed multiple myeloma (RRMM) remains a big clinical challenge, due to its biological and clinical complexity. Leading hematologists have performed many randomized controlled trials (RCTs) worldwide, and their findings were summarized in a recently published network met...
Autores principales: | Luo, Xian-Wu, Du, Xue-Qing, Li, Jie-Li, Liu, Xiao-Ping, Meng, Xiang-Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109665/ https://www.ncbi.nlm.nih.gov/pubmed/30174457 http://dx.doi.org/10.2147/CMAR.S166640 |
Ejemplares similares
-
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment
por: Dimopoulos, Meletios A., et al.
Publicado: (2022) -
Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
por: Nijhof, Inger S., et al.
Publicado: (2017) -
Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity
por: Cornell, R F, et al.
Publicado: (2016) -
Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019) -
Treatment of relapsed and refractory multiple myeloma
por: Lee, Ji Hyun, et al.
Publicado: (2020)